Volume 122, Issue 6 , Pages 582.e1-582.e9, June 2009
C-Reactive Protein Elicits White Blood Cell Activation in Humans
Abstract
Objective
Consistent epidemiologic evidence suggests that acute infections increase the risk for acute cardiovascular events. We tested in humans whether activation of peripheral leukocytes in reaction to the administration of recombinant human C-reactive protein (rhCRP) may provide a mechanism for infectious diseases to promote atherosclerotic disease.
Methods and Results
By using quantitative real-time polymerase chain reaction analysis, whole-blood expression profiles were analyzed for 95 inflammatory markers before and after infusion of 1.25 mg/kg rhCRP in 5 male volunteers. Relevant transcript levels were measured at baseline and 4 and 8 hours after rhCRP-infusion. CRP caused significant up-regulation of matrix metalloproteinase (MMP)-9, monocyte chemoattractant protein (MCP)-1, plasminogen activator urokinase, macrophage inflammatory protein 1α, and nuclear factor of kappa B inhibitor mRNAs in peripheral leukocytes. mRNA up-regulation of MMP-9 and MCP-1 was 17- and 11-fold, respectively. The corresponding increase in plasma protein levels of MMP-9 (78
±
32 ng/mL to 109
±
41 ng/mL; P
=
.014) and MCP-1 (312
±
92 pg/mL to 2590
±
898 pg/mL; P
=
.007) closely mirrored mRNA findings. Also, in whole-blood culture stimulation assays, CRP induced proinflammatory changes. Notably, heat inactivation abolished the capacity of CRP to evoke these proinflammatory changes, excluding a role for contaminants within the purified CRP preparation.
Conclusion
CRP elicits activation of peripheral leukocytes with ensuing secretion of plaque-destabilizing mediators. These findings are consistent with the hypothesis that infectious diseases trigger manifestations of atherosclerosis, in which CRP elevation might contribute to the onset of cardiovascular events.
Keywords: Atherosclerosis, Cardiovascular everts, C-reactive protein, Infection, Leukocytes
To access this article, please choose from the options below
Funding: This work was in part supported by a grant from Pfizer, which had no involvement in the data analysis/interpretation or writing the manuscript. John J. P. Kastelein is an established investigator of The Netherlands Heart Foundation (2000D039).
Conflict of Interest: None.
Authorship: All authors had access to the data and played a role in writing.
PII: S0002-9343(09)00116-8
doi:10.1016/j.amjmed.2008.11.032
© 2009 Elsevier Inc. All rights reserved.
Volume 122, Issue 6 , Pages 582.e1-582.e9, June 2009

